Henry Schein, Inc.

DB:HS2 Stock Report

Market Cap: €8.4b

Henry Schein Valuation

Is HS2 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of HS2 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: HS2 (€66.76) is trading below our estimate of fair value (€70.54)

Significantly Below Fair Value: HS2 is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for HS2?

Key metric: As HS2 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for HS2. This is calculated by dividing HS2's market cap by their current earnings.
What is HS2's PE Ratio?
PE Ratio27.2x
EarningsUS$314.00m
Market CapUS$8.63b

Price to Earnings Ratio vs Peers

How does HS2's PE Ratio compare to its peers?

The above table shows the PE ratio for HS2 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average24.1x
ILM1 Medios
26.5x40.9%€341.3m
FME Fresenius Medical Care
19.4x17.0%€12.8b
SYAB SYNLAB
27.7x-11.4%€2.5b
AFX Carl Zeiss Meditec
22.8x16.1%€4.1b
HS2 Henry Schein
27.2x26.7%€8.6b

Price-To-Earnings vs Peers: HS2 is expensive based on its Price-To-Earnings Ratio (27.2x) compared to the peer average (24.1x).

Price to Earnings Ratio vs Industry

How does HS2's PE Ratio compare vs other companies in the European Healthcare Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
HS2 27.2xIndustry Avg. 18.9xNo. of Companies6PE01020304050+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: HS2 is expensive based on its Price-To-Earnings Ratio (27.2x) compared to the European Healthcare industry average (18.4x).

Price to Earnings Ratio vs Fair Ratio

What is HS2's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

HS2 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio27.2x
Fair PE Ratio31.9x

Price-To-Earnings vs Fair Ratio: HS2 is good value based on its Price-To-Earnings Ratio (27.2x) compared to the estimated Fair Price-To-Earnings Ratio (31.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst HS2 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€66.76
€71.50
+7.1%
9.7%€79.30€52.55n/a12
Dec ’25€73.24
€70.64
-3.5%
10.2%€78.37€51.93n/a11
Nov ’25€64.40
€69.11
+7.3%
10.2%€76.76€50.86n/a11
Oct ’25€65.18
€65.64
+0.7%
11.6%€74.35€49.27n/a11
Sep ’25€63.76
€67.87
+6.4%
13.2%€84.17€50.32n/a11
Aug ’25€66.50
€73.41
+10.4%
12.2%€85.10€55.50n/a11
Jul ’25€59.42
€74.05
+24.6%
9.6%€86.14€60.86n/a12
Jun ’25€63.34
€73.53
+16.1%
9.4%€85.18€60.18n/a12
May ’25€68.00
€75.78
+11.4%
7.8%€84.59€61.09n/a13
Apr ’25€69.66
€74.28
+6.6%
7.6%€82.21€59.37n/a13
Mar ’25€70.56
€73.94
+4.8%
7.8%€83.27€60.14n/a13
Feb ’25€69.10
€69.24
+0.2%
7.4%€75.54€59.88n/a12
Jan ’25€68.48
€68.54
+0.09%
7.3%€75.96€60.21€67.1612
Dec ’24€62.98
€68.08
+8.1%
7.0%€75.38€59.75€73.2412
Nov ’24€61.20
€75.52
+23.4%
7.1%€85.17€65.29€64.4012
Oct ’24€69.96
€77.14
+10.3%
7.4%€89.00€65.33€65.1812
Sep ’24€70.36
€75.45
+7.2%
8.4%€87.44€62.85€63.7613
Aug ’24€71.88
€75.37
+4.9%
8.3%€86.86€62.43€66.5013
Jul ’24€74.34
€77.32
+4.0%
8.5%€89.36€64.23€59.4213
Jun ’24€68.42
€76.22
+11.4%
8.8%€87.43€62.84€63.3413
May ’24€73.26
€76.27
+4.1%
8.9%€87.83€62.48€68.0013
Apr ’24€73.98
€79.32
+7.2%
9.0%€91.97€65.42€69.6612
Mar ’24€73.61
€78.39
+6.5%
9.5%€90.98€64.72€70.5612
Feb ’24€79.05
€76.84
-2.8%
9.3%€92.02€65.07€69.1012
Jan ’24€75.24
€76.78
+2.0%
10.0%€93.27€65.95€68.4812

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 10:09
End of Day Share Price 2025/01/02 00:00
Earnings2024/09/28
Annual Earnings2023/12/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Henry Schein, Inc. is covered by 38 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jeffrey JohnsonBaird
Ishan MajumdarBaptista Research
Lawrence MarshBarclays